Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Deferasirox
Therapeutic Area : Hematology
Study Phase : Phase II
Sponsor : Catalent Pharma Solutions
Deal Size : Undisclosed
Deal Type : Collaboration
Details : DisperSol’s active programs include, DST-0509 about to enter Phase 3 for iron overload disorder, DST-2970 in Phase 2 for refractory metastatic prostate cancer and DST-8294 for treatment of clotting disorders.
Brand Name : DST-0509
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 02, 2021
Lead Product(s) : Deferasirox
Therapeutic Area : Hematology
Highest Development Status : Phase II
Sponsor : Catalent Pharma Solutions
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?